Good clinical practice

ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BIVI

Retrieved on: 
Saturday, February 17, 2024

WHAT TO DO NEXT: To join the BioVie class action, go to https://rosenlegal.com/submit-form/?case_id=21342 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioVie class action, go to https://rosenlegal.com/submit-form/?case_id=21342 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

BioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman

Retrieved on: 
Friday, February 16, 2024

SAN FRANCISCO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .
  • The litigation focuses on the propriety of BioVie’s disclosures concerning its adherence to Good Clinical Practice (“GCP”) and protocols related to its Phase 3 clinical trial of NE3107, a potential Alzheimer’s disease drug.
  • ]” This news drove the price of BioVie shares down $1.25, or almost 30% lower, on Nov. 9, 2023.
  • “We’re focused on investors’ losses and are investigating whether BioVie may have intentionally concealed GCP and protocol violations,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)

Retrieved on: 
Thursday, February 15, 2024

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • ]”
    On this news, BioVie’s stock price fell $1.25, or 29.3%, to close at $3.01 per share on November 9, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

BIOVIE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, February 15, 2024

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and reminds investors of the March 19, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $25,000 investing in BioVie stock or options between August 5, 2021 and November 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Upon trial completion, the Company found significant deviation from protocol and Good Clinical Practice (GCP) violations at 15 sites.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioVie’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 15, 2024

According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Key Points: 
  • According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As a result, ADM delayed its Q4 and FY 2023 earnings release and withdrew its outlook for the Nutrition segment.
  • For more information on the ADM class action go to: https://bespc.com/cases/ADM

DEADLINE ALERT for MBLY, FTFT, BIVI, and BTI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Wednesday, February 14, 2024

LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BIVI

Retrieved on: 
Tuesday, February 13, 2024

WHAT TO DO NEXT: To join the BioVie class action, go to https://rosenlegal.com/submit-form/?case_id=21342 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioVie class action, go to https://rosenlegal.com/submit-form/?case_id=21342 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

DEADLINE ALERT for CMI, MBLY, FTFT, BIVI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Tuesday, February 13, 2024

BENSALEM, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

BIVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioVie Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, February 13, 2024

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/BIVI .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/BIVI .
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in BioVie you have until March 19, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

BioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman

Retrieved on: 
Monday, February 12, 2024

SAN FRANCISCO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .
  • The litigation focuses on the propriety of BioVie’s disclosures concerning its adherence to Good Clinical Practice (“GCP”) and protocols related to its Phase 3 clinical trial of NE3107, a potential Alzheimer’s disease drug.
  • ]” This news drove the price of BioVie shares down $1.25, or almost 30% lower, on Nov. 9, 2023.
  • “We’re focused on investors’ losses and are investigating whether BioVie may have intentionally concealed GCP and protocol violations,” said Reed Kathrein, the Hagens Berman partner leading the investigation.